Bayer Crop Science Canada Introduces Raxil Rise, A New Standard in Cereal Seed Treatment
September 17, 2025
Calgary, AB September 17, 2025 — Bayer Crop Science Canada announced the launch of Raxil® Rise, a new cereal seed treatment that offers powerful, broad-spectrum control against seed-and soil-borne diseases. Raxil Rise builds off 25 years of trusted performance from Raxil, the number one cereal seed treatment brand* in Western Canada.
“Raxil Rise demonstrates Bayer’s continued commitment to Canadian farmers,” says Bryan Bryson, Bayer Crop Science Marketing Portfolio Lead for Crop Protection in Western Canada. “Given the unpredictability of farming, seed treatments are a critical step to maximize the yield and quality of your seed investments, but they need be simple to use and effective—which is where Raxil shines. We’re proud to offer an enhanced disease product with Raxil Rise that delivers the best-in-class application experience farmers expect.”
Key highlights of Raxil Rise:
Enhanced broad-spectrum seed-and soil-borne disease control: Raxil Rise leverages the addition of penflufen (7), for enhanced protection against yield-robbing diseases, like true loose smut and Fusarium
Micro-dispersion formulation and enhanced coverage: Bayer’s formulation ensures a best-in-class application experience, including excellent seed coverage, outstanding flowability in varying temperatures, and low dust-off, along with an enriched colour for confident coverage you can see
Four disease-fighting active ingredients: Raxil Rise uses four fungicidal actives for complete contact and systemic disease protection, including Penflufen (7), Tebuconazole (3), Prothioconazole (3) and Metalaxyl (4)
“There’s been a need for enhanced disease control in cereals, specifically with Fusarium, and true loose smut (TLS) in barley,” says Rory Cranston, Bayer Crop Science Canada’s Cereals Technical Strategy Lead. “With the evolution of the Raxil brand, we’ve added the active ingredient penflufen (group 7) to boost its effectiveness against yield-robbing diseases. Using micro dispersion technology, it ensures each seed receives the best coverage possible with our enhanced pink colourant, so you can be confident that you’re covered. It also dries quickly and stays there throughout the treating, auguring and seeding process.”
This spring, Bayer conducted more than 100 pre-commercial Raxil Rise trials across Western Canada with growers, seed treaters and agronomists. “When it came to treating, Raxil Rise was easy to use, flowed well, coverage was excellent and there (were) no issues with flaking or gumming up treating or seeding equipment,” said Emily Barteaux, an Independent Agronomist with 305 Agronomy who trialed Raxil Rise this year. “Overall, really impressed with how it handles in comparison to the top tier experience we expect after using Raxil PRO for so long.”
Raxil Rise is available for purchase in the 2026 growing season. Visit www.RaxilRise.ca for more information.
*Source: 2025 AGDATA West Cereal Seed Treatment Report – Cereal Seed Treatment
-30-
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people, and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses before special items amounted to 6.2 billion euros.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
For further information or to arrange an interview, contact:
Communications Department
Bayer Inc.
mediacanada@bayer.com
